Brownbag Talk Series
SATRN holds lunchtime brownbag meetings twice per month, offering a chance for our members to connect and learn from each other on a regular basis. Each brown bag meeting features a talk by a member of our network or a guest speaker. These are often research presentations, integrating and analyzing scientific evidence on a topic related to substance use disorder and/or mechanisms of addiction. Other talks may provide training on a methodological approach; invite feedback on a new research idea; or communicate the experience and perspective of practitioners in the field.
All SATRN affiliates are invited and encouraged to attend! Information on upcoming talks are advertised in the SATRN newsletter, as well as on this site. To be added to the list to receive email and Outlook invitations for each meeting and/or the newsletter mailing list, please email ceavila3@asu.edu
Upcoming Talks
ASU Southwest Interdisciplinary Research Center (SIRC) Opioid Initiatives
Natasha Mendoza, Ph.D.
Monday, April 22
12:00 PM | Virtual
Since 2019, the Opioid Initiatives at Arizona State University's Southwest Interdisciplinary Research Center (SIRC), supported by AHCCCS and SAMHSA, have been pivotal in combating Arizona's opioid syndemic. Dr. Natasha Mendoza, a social work researcher with over two decades of experience, leads this effort. The Opioid Initiatives team has developed crucial resources for behavioral healthcare providers, including curriculum related to medication for opioid use disorders, overdose prevention, and recovery homes. This presentation will highlight the significant contributions and ongoing work of ASU's Opioid Initiatives under Dr. Mendoza's leadership, offering key insights into addressing Arizona’s opioid syndemic.
Past Talks
No Wrong Door: Connecting Support for SUD, Mental Health, and Social Determinants of Health
Nicole Dupuis-Witt, M.P.H. and Michelle (Lani) Shiota, Ph.D.
April 8, 2024
Struggles with substance use disorder, mental illness, housing insecurity, and unemployment typically create a downward spiral where each heightens vulnerability to the others. In "no wrong door" social programs, seeking any one of these services triggers screening for the rest, and connection to someone who can coordinate all needed support. SATRN Director Lani Shiota and City of Phoenix Public Health Advisor Nicole Witt will lead a discussion of what this approach might look like in Phoenix - a first step in preparing for a planned proposal to the new federal ARPA-H agency to fund such an initiative.
Exploring the Social Determinants of Substance Use Disorders among Young Adults Experiencing Homelessness in the Southwest United States
Shiyou Wu, Ph.D.
February 19, 2024
This presentation briefly introduced the SDoHH project and shared the preliminary findings on the prevalence of substance use and Substance Use Disorder (SUD) among young adults experiencing homelessness. Additionally, using primary data from both hot and cold seasons, Dr. Wu explored the seasonal differences in the social determinants of SUD among this population at individual, interpersonal, and intrapersonal levels.
View the presentation slides below:
Opioid Vaccines for Addiction and Overdose
Kathryn M. Frietze, Ph.D.
January 22, 2024
Best-known for their role in preventing infectious disease, vaccines are also a novel approach for treatment of opioid use disorder. Dr. Frietze will provide an overview of opioid vaccines, their proposed use in treating opioid use disorder and overdose, and discuss her efforts to develop vaccines against opioids.
Watch the full talk here.
Arizona's Opioid Settlement Funds: Need for Grassroots Advocacy and a How-To Kit
Moderated by SATRN Director, Michelle "Lani" Shiota, Ph.D.
December 4, 2023
Opioid settlement funds heading to Arizona have the potential to support high-impact efforts to reduce substance use disorder-related harms. However, there's a catch - Arizona legislature approval is required to spend nearly half of the money! This community discussion focused on exploring this issue and concrete, simple steps SATRN affiliates (and other Arizona constituents!) can take to help ensure these funds are invested appropriately.
Do I want to share my substance use disorder medical records?
Adela Grando, Ph.D.
November 6, 2023
Dr. Grando studies informatics solutions to support patients’ desires to control the sharing of sensitive medical records. Dr. Grando will discuss the 5-year, NIDA-funded, Substance Use Health Record Sharing (SHARES) grant that she leads.
SHARES is the first substance use disorder medical record-sharing study to engage patients (including Spanish speakers), providers, and expert stakeholders from informatics, medicine, ethics, law, and policy. SHARES collaborates with five clinical sites in Arizona and with a national Advisory Board to propose consent technology to balance patient stigma with providers' “need to know” to provide safe care. SHARES measures the impact of SUD medical record segmentation on care and patient outcomes.
Watch the full talk here.
Promoting Engagement in Substance Use Prevention Interventions
Stephanie Marita Carpenter, Ph.D.
October 16, 2023
Dr. Carpenter studies emotions and engagement, and their impact on health behaviors, using precision health methods that adapt to the unique needs of the individual. Her research uses optimization studies to construct engaging adaptive health behavior change interventions. In her talk, Dr. Carpenter will discuss research on the development of strategies to promote engagement in prevention interventions for young adults at risk of binge drinking.
Cultural Humility in Working with Diverse Clients and Trainees
Ana Maria Melendez Guevara, Ph.D., Kamryn Morris, Ph.D., & Kimberly Osborne, Ph.D.
April 17, 2023
In clinical and academic settings alike, appreciation is growing for the importance of sensitivity to clients' and trainees' varying cultural backgrounds. Moreover, the realities of living with prejudice, discrimination, and inequity have become increasingly prominent in the national conversation, and these issues come up in therapeutic and educational settings. Those engaging in these conversations often come from different backgrounds, but explicit training in how to approach such conversations is rare. While one option is to aspire to competence in specific cultural contexts represented among one's clients or students, this "cultural competence" approach has drawbacks. This talk presented an alternative approach - cultural humility - that honors each individual's intersecting identities and experience.
Talk Highlights
- Conversations about culture and identity are important, and help improve rapport and quality of care, especially between those in positions of authority and clients/mentees.
- Cultural humility is an approach to actively engaging another’s identity and cultural perspective with open-minded inquiry. Unlike cultural competency, cultural humility emphasizes intersectionality of identity and within-group diversity of experience.
- The cultural humility approach encourages reflecting on and bridging status differences between providers/instructors and clients/students; and emphasizes lifelong learning, acceptance of making mistakes and learning, rather than achieving static competence.
- Recommendations: create safe space for conversations about culture; engage with these conversations by asking questions, listening openly; self-reflect on own background and privilege; advocate for diversity and equity, in and beyond the workplace.
Watch the full talk here.
Psychedelic-Assisted Therapy for Mental Health and Substance Use Disorders
Candace Lewis, Ph.D.
April 3, 2023
Dr. Lewis's research focuses on the impact of early life social experiences on epigenetic regulation of gene systems involved in mental health; the relationships between peripheral epigenetics and brain structure, function, microbiome composition and behavior; and the potential of psychedelic-assisted therapy to reduce symptoms through psychological healing and epigenetic alterations. In this brownbag talk, Dr. Lewis discusses the history, modern, and potential future landscapes of psychedelic-assisted therapy.
Watch the full talk here.
COMMUNITY DISCUSSION: The Opioid Settlement Fund and Extraordinary Science
Moderated by SATRN Director Michelle "Lani" Shiota, Ph.D.
March 20, 2023
Planning is underway for deployment of funds from the national opioid settlement - $548 million in Arizona over the next 18 years - to alleviate harm associated with substance use disorder. Funds will be disbursed through public health organizations at the city, county and state levels; SATRN and its affiliates are already engaged with needs assessment and related efforts by Maricopa County and the City of Phoenix. The long-term commitment of these resources, and the potential for strategic, coordinated action among agencies, creates an extraordinary opportunity for intervention. It also creates an opportunity for extraordinary science, with a comparably strategic, coordinated, large-scale approach.
Addiction Treatment through Telehealth: Stigma, Evidence, and Best Practice
Matt Meier, Ph.D.
February 27, 2023
In response to the COVID-19 pandemic, there was exponential growth in the use of telehealth services for mental health and substance use disorder treatment. In an effort to avoid reducing access to desperately needed services, many providers implemented telehealth programs with limited training or preparation. This talk reviews recent evidence on the effectiveness of telehealth treatment, as well as implications for practitioners.
Talk Highlights
- Benefits of telehealth treatment include increased access for those in rural and underserved geographic areas, convenience for clients, avoiding stigma associated with receiving treatment. Limitations may include access to and comfort level surrounding the necessary technology, and possible lack of privacy.
- Although more providers strongly prefer in-person sessions, overall evidence suggests telehealth services are as effective as in-person services, both in terms of client perception of rapport and treatment outcomes.
- Feelings of discomfort and skepticism are natural for clinicians new to telehealth care. Dr. Meier recommends clinicians address personal concerns surrounding telehealth and addiction, and participate in training to develop telehealth-specific competencies.
Watch the full talk here.
The Science of Emotion Regulation: Implications for Prevention, Treatment, Policy
Michelle "Lani" Shiota, Ph.D.
February 13, 2023
Life stress is a well-established risk factor, both for the development of substance use disorder and for relapse. Strong emotion regulation skills may help people manage substance use in healthier ways; calls are growing for training/curricula appropriate for SUD-related prevention and treatment, as well as for the general population. This talk summarizes the current state of the scientific literature on emotion regulation, and suggests concrete implications for practice as well as crucial directions for future research.
Talk Highlights
- Stress and distress led to increased craving, impaired impulse control and delay of gratification, self-medication, and difficulties with self-regulation.
- While healthy emotion regulation can help break this link, there is no “one size fits all” emotion regulation strategy appropriate for all contexts.
- Emotion regulation coaching should promote flexibility: ability to identify and deploy the strategy/ies most likely to be beneficial in a given situation.
- A strong “toolkit” likely includes strategic situation selection; problem solving; savoring pleasant experiences; reappraisal facilitating a positive mindset; and activities that directly reduce physiological arousal.
Watch the full talk here.
Nothing much changed: Patient experience of federal flexibilities for methadone and buprenorphine during COVID, Arizona 2022
Beth Meyerson Ph.D. & Danielle Russell, M.S.
November 14, 2022
In March 2020, federal regulators allowed flexibilities to facilitate access to methadone and buprenorphine while decreasing risk of COVID exposure. The study, MOUD (Medication for Opioid Use Disorder) Access Policy Impact (MAPI), examined the impact of these recommended policy changes through statewide interviews with people on methadone and buprenorphine during COVID in Arizona.
Talk Highlights
- Federally-recommended flexibilities included telehealth options and increased multi-day dosing accommodations.
- Study findings indicate that few Arizonans on methadone/buprenorphine actually experienced these benefits.
- Providers were able to conduct telehealth appointments remotely, but patients were typically still required to be in the clinic.
- The majority of methadone patients with high COVID risk were still required to go to the clinic daily for doses, rather than being offered multi-day dosing.
- Practical implications: COVID-era flexibilities should be required (as distinct from recommended) on an ongoing basis; more patient advocacy frameworks for clinic and state policy adoption are needed.
Read more about their research here. Watch the full talk and discussion here.
The Yavapai Reentry Project: Providing Support, Restoration and Hope
Merilee Fowler & Clarissa Nelson
October 31, 2022
Justice-involved individuals face significant risk related to substance use disorder upon release from incarceration and reentry into society. The Yavapai County Reentry Project (YRP) was formed in 2012 to provide support to individuals returning home to Yavapai County from prison. This grassroot effort had no set funding, but relied on volunteers wanting to make a difference in their community.
Talk Highlights
- In Arizona the rate of individuals returning into custody within three years of release is 40%.
- Challenges individuals face after release include securing employment, housing, health care, and lack of emotional and behavioral support. The YRP matches participants with a personal community coach who provides support and resources to overcome these barriers.
- The YRP has trained six additional counties in developing their own reentry programs; and continue to support government and community organizations.
Watch Merilee & Clarissa's talk here.
Measurement-Based Care: Behavioral Health Providers' Use and Attitudes
Marisa Domino, Ph.D.
October 17, 2022
Despite robust evidence for efficacy of measurement-based care (MBC) in behavioral health care, studies suggest limited adoption of MBC in practice. This talk presents results from a survey of behavioral health care providers on utilization of MBC, beliefs about MBC, and barriers to its adoption.
Talk Highlights
- In Measurement Based Care (MBC) providers collect data from individual patients to track their progress and plan treatment. While common practice in physical health care, MBC is less common in behavioral health.
- Fewer than half of behavioral health care providers reported using MBC with at least half of their patients; perceived low clinical utility of MBC was strongly associated with lower MBC use.
- Behavioral health providers who offer specialized care, were more recently trained, and/or practice in rural areas were more likely to report using MBC in their practice.
- Possible barriers to using MBC include administrative burden, lack of training opportunities, and lack of knowledge about the benefits of implementing MBC.
Medication-Assisted Smoking Cessation Treatment: Recent Research on Cytisine
Scott Leischow Ph.D
October 3, 2022
Smoking remains a leading cause of preventable disease and mortality. The most effective treatment currently available is combination of the medication varenicline with behavioral support. However, the most popular brand of varenicline (Chantix) has been pulled from the market due to concerns about ingredients. In this talk, Dr. Leischow discusses Cytisine, a closely related, naturally occurring substance and a promising alternative medication for smoking cessation.
Talk Highlights
- Cytisine is a naturally occurring substance with a chemical structure similar to varenicline, and has been shown to be as effective as varenicline in helping smokers quit with minimal side effects.
- Cytisine may be a more affordable option, as varenicline is very expensive for those without health insurance.
- Although cytisine is approved and available in multiple countries, additional research is needed in the US before it can be submitted to the FDA for approval as a medication for smoking cessation. That research is underway.
Environmental Contaminants in Cannabis: Hidden Health Hazards to Recreational Users and Medical Patients
Maxwell Leung Ph.D
September 19, 2022
Dr. Maxwell Leung is an Assistant Professor at the Pharmacology and Toxicology program at ASU West Campus. His research focuses on the potential environmental contaminants which can be found in cannabis, including pesticides and microbes. Each poses potential health risks – alone and/or in interaction with cannabis – with effects being studied in labs today.
Talk Highlights
- Because cannabis is illegal under federal law, there are no national-level regulations. Due to different contaminant restrictions across states, a batch of cannabis could pass health regulations in one state but not another.
- For those who use cannabis as part of treatment for a variety of illnesses, particularly those who are immune-compromised, the lack of information and regulation around contaminants is a serious concern.
- Further research and information is needed to inform effective health and safety regulations for cannabis.
Harm Reduction Saves Lives
Haley Coles
April 11, 2022
Harm reduction is the radical principle of accepting that drug use exists in our society. Sonoran Prevention Works is a nonprofit organization focused on harm reduction, whose mission is to build a safe and healthy Arizona for people who use drugs. Sonoran Prevention Works advocates for individual and systemic change in how communities approach people who use drugs, and issues surrounding drug use disorders.
Talk Highlights
- Originally Phoenix Harm Reduction Organization, Sonoran Prevention Works began practicing and advocating for harm reduction in 2010.
- Sonoran Prevention Works is the largest Naloxone distributor in the country, and has helped pass 3 laws in Arizona.
- The program works to reduce stigma around drug use and substance use disorders through education initiatives on the history of drug use, developing harm reduction projects, supporting community based participatory research were people with lived experiences in drug use and drug use disorder are heard, and continued work with policy makers to create policies and laws that support harm reduction efforts.
Access a recording of the talk here.
Young adult opioid misuse indicates a general tendency toward substance use and is strongly predicted by general substance use risk
Sabrina Oesterle, Ph.D. & Danielle Pandika, Ph.D.
March 14, 2022
This study uses recent data from the Community Youth Development Study and structural equation modeling to demonstrate that young adult opioid misuse mostly reflects a general tendency to use substances.
Talk Highlights
- Risk pathways to opioid misuse are mostly shared with those for other commonly used substances (i.e. alcohol, tobacco, and marijuana).
- Practical implication: expanded implementation of existing substance use prevention programs may be an effective strategy for combating the opioid crisis in young adult populations.
Access the presentation slides here:
Early treatment predictors of Medication Assisted Treatment outcomes for Opioid Use Disorder
Will Corbin, Ph.D.
February 21, 2022
Funded by a SATRN Glen J. Swette Seed Grant, this project in partnership with Community Medical Services (CMS) examines early treatment predictors of Medication Assisted Treatment (MAT) outcomes for individuals with Opioid Use Disorder - specifically consistency of early dosing and size of initial dose. Dr. Corbin discusses ways researchers can establish positive collaborative relationships with community partners, summarizes the study methods and preliminary findings, and discusses next steps for their team and research.
Talk Highlights
- Study hypotheses were that more consistent dosing and larger initial dose would be associated with better MAT outcomes, and that clinics with blocked dosing (i.e., same set time window for dosing each day) would have better outcomes than those without blocked dosing.
- Preliminary findings at the individual level were consistent with hypotheses. At the clinic level, however, patients with blocked dosing had worse retention and dose stability than patients without.
- Practical implication: Blocked dosing may create an unintended treatment barrier.
Access a recording of the talk here.
The Probation Journey
Shanda Breed
January 24, 2022
Changing lives starts with changing as individuals and as a system. Probation partners want to be part of the solution, rather than the recidivism revolving doors. Shanda Breed, a program Manager for the Adult Probation Services Division at the Arizona Supreme Court, discusses the reality of probation in Arizona, how the government is reexamining their processes to better support the needs of formerly incarcerated individuals, as well as how communities can help.
Talk Highlights
- The Arizona Supreme Court is examining if their rules and regulations for recently incarcerated individuals are realistic.
- To help build empathy and understanding within the community, the courts have created a simulation training to walk participants through what it is like to be released from prison, encountering the steps and barriers they would have to navigate in order to successfully reenter their community.
- Greater understanding of the challenges formerly incarcerated individuals face, both within the legal system and in their personal lives, is important to create a better probation system for Arizona.
Access a recording of the talk here.
“They say it’s fentanyl, but they honestly look like Perc 30s:” Lay experiences with the increasing street availability of counterfeit pills containing non-pharmaceutical fentanyl
Raminta Daniulaityte, P.hD.
November 15, 2021
Worsening of the overdose crisis in the U.S. has been linked to continuing proliferation of non-pharmaceutical fentanyl, fentanyl analogs, and other novel synthetic opioids (NSO). The new wave of NSO spread in the U.S. is fueled by increased presence of counterfeit pain pills that contain fentanyl and other NSOs. This qualitative study aims to detail and contextualize attitudes and experiences with counterfeit pain pill use among people who use illicit opioids (PWUO) in Arizona.
Talk Highlights
- Researchers conducted interviews with 22 individuals in Arizona who have used illicit opioids in the past 30 days, and/or participated in treatment for opioid use disorder in the past 12 months.
- Interviews give insight into the increased access and availability of fentanyl in Arizona and the perceived risks and ideas of illicit opioid use.
- Study findings highlighted ideas for harm reduction and important targets of policy change, particularly increased access to fentanyl testing strips.
Access the presentation slides here:
Can E-cigarettes Help Smokers Quit: Exploring the Science, Policy and Future Research Directions
Scott Leischow, Ph.D.
September 9, 2021
Helping smokers quit remains one of the top public health challenges, as few smokers who try to quit on any one occasion are successful. The most effective treatment is behavioral support combined with either varenicline or two types of nicotine replacement used together. In this talk, Dr. Leischow discusses the controversial use of e-cigarettes as a tool for smoking cessation.
Talk Highlights
- Since e-cigarettes have been on the market, many smokers have used them to make quit attempts. However, e-cigarettes have not been formally tested and approved by the FDA for that purpose.
- Multiple studies have explored the, but the definitive studies have not been completed. Preliminary findings from several studies suggest e-cigarettes may faciliate smoking cessation for up to 6 months.
- More research is required for researchers to feel comfortable recommending e-cigarettes as part of a quit attempt, and to provide smokers with the information needed to make an informed choice when they decide to quit smoking.
Access the presentation slides here: